Journal article

Re-challenge chemotherapy with gemcitabine plus carboplatin in patients with non-small cell lung cancer

Khurum Khan, Gerard G Hanna, Lynn Campbell, Paula Scullin, Adnan Hussain, Ruth L Eakin, Jonathan McAleese

CHINESE JOURNAL OF CANCER | SUN YAT SEN UNIV MED SCI WHO | Published : 2013

Abstract

Despite recent improvements to current therapies and the emergence of novel agents to manage advanced non-small cell lung cancer (NSCLC), the patients' overall survival remains poor. Re-challenging with first-line chemotherapy upon relapse is common in the management of small cell lung cancer but is not well reported for advanced NSCLC. NSCLC relapse has been attributed to acquired drug resistance, but the repopulation of sensitive clones may also play a role, in which case re-challenge may be appropriate. Here, we report the results of re-challenge with gemcitabine plus carboplatin in 22 patients from a single institution who had previously received gemcitabine plus platinum in the first-li..

View full abstract